Archives
Opinion: Vaccine Nationalism Harms Everyone and Protects No One
5 Feb, 2021 | 01:45h | UTCVaccine Nationalism Harms Everyone and Protects No One – Foreign Policy
Related: Jeremy Farrar: Until we are all safe, no one is safe. Covid is a global problem – The Guardian AND Covid-19: WHO warns against “vaccine nationalism” or face further virus mutations – The BMJ AND ‘Vaccine nationalism’ threatens global plan to distribute COVID-19 shots fairly – Science AND WHO chief warns against ‘catastrophic moral failure’ in COVID-19 vaccine access – United Nations
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Study: Adults between 20 and 49 years responsible for most Covid-19 spread
5 Feb, 2021 | 01:43h | UTCAge groups that sustain resurging COVID-19 epidemics in the United States – Science
Commentaries: Adults 20 to 49 may have driven 72% of US COVID-19 surges – CIDRAP AND Younger adults responsible for most of COVID-19 spread: Study – ABC News
Study: Single dose Pfizer Covid-19 vaccine effectiveness estimated at 90% after 21 days
5 Feb, 2021 | 01:43h | UTCCommentaries: One Pfizer/BioNTech jab gives ‘90% immunity’ from Covid after 21 days – The Guardian AND Expert reaction to preprint reanalysing study of real-world Pfizer vaccination outcomes after one dose from Israel – Science Media Centre
Commentary on Twitter
A study on "real world" effects of vaccination in Israel
🥳 Single dose 90% effective at 21d 🥳
"…results coming from Israel support the UK policy of extending the gap between doses by showing that a single dose can give a high level of protection."https://t.co/smnZUPJkZp
— Alasdair Munro (@apsmunro) February 4, 2021
Phase 1/2 Clinical Trial: CoronaVac is safe and well tolerated in older adults. Neutralizing antibodies were detected in over 90% of participants in all groups
5 Feb, 2021 | 01:41h | UTCCommentary: Inactivated COVID-19 vaccines to make a global impact – The Lancet Infectious Diseases
Commentary on Twitter
https://twitter.com/hildabast/status/1357281190198140929
New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work
5 Feb, 2021 | 01:41h | UTC
Impact of COVID-19 on cancer care has been ‘profound’, warns UN health agency
5 Feb, 2021 | 01:38h | UTCImpact of COVID-19 on cancer care has been ‘profound’, warns UN health agency – UN News
Dialysis patients have 4-fold greater risk of dying from COVID-19
5 Feb, 2021 | 01:39h | UTCNews Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal
Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal
Why the WHO won’t call it the ‘U.K. variant’, and you shouldn’t either
5 Feb, 2021 | 01:40h | UTCWhy the WHO won’t call it the ‘U.K. variant’, and you shouldn’t either – CTV News
Related: The world needs a single naming system for coronavirus variants – Nature
Policy Statement: Antibiotic Stewardship in Pediatrics
4 Feb, 2021 | 01:21h | UTCAntibiotic Stewardship in Pediatrics – Pediatrics
Commentary: Guidance Provided for Antibiotic Stewardship in Pediatrics
COVID’s mental-health toll: how scientists are tracking a surge in depression
5 Feb, 2021 | 01:36h | UTCCOVID’s mental-health toll: how scientists are tracking a surge in depression – Nature
Related: Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic – JAMA Psychiatry AND Mental Health, COVID-19, and the Invisible Pandemic on the Horizon – Mayo Clinic Proceedings
Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension
4 Feb, 2021 | 01:18h | UTC
Commentary on Twitter
Does induced hypothermia/targetted temp management improve outcomes in patients with traumatic brain injury?
Maybe or maybe not
But this trial slow to cool, not very cool, underpowered and mod rate of dropout
Prob does not answer questionhttps://t.co/UGRFmUVNV0 pic.twitter.com/c0iDqj2l2e
— Graham Nichol (@grahamnichol) January 29, 2021
Prevalence and trends in tobacco use among adolescents aged 13–15 years in 143 countries, 1999–2018: findings from the Global Youth Tobacco Surveys
4 Feb, 2021 | 01:20h | UTCPrevalence and trends in tobacco use among adolescents aged 13–15 years in 143 countries, 1999–2018: findings from the Global Youth Tobacco Surveys – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Global Youth Tobacco Surveys data from 13–15-year-olds in 140 countries, suggests 40% of countries show no progress in reducing cigarette smoking in adolescents over the past 20 years. Read more findings from the @LancetChildAdol study: https://t.co/qlHzvHHdOD
— The Lancet (@TheLancet) February 3, 2021
State of the Art Review: Uveitis for the non-ophthalmologist
4 Feb, 2021 | 01:22h | UTCUveitis for the non-ophthalmologist – The BMJ (free for a limited period)
Consensus statement for perioperative care in lumbar spinal fusion: Enhanced Recovery After Surgery (ERAS®) Society recommendations
4 Feb, 2021 | 01:15h | UTC
German 2021 guideline update on acute therapy and management of anaphylaxis
4 Feb, 2021 | 01:17h | UTC
Systematic review: Telerehabilitation for chronic respiratory disease
4 Feb, 2021 | 01:08h | UTCTelerehabilitation for chronic respiratory disease – Cochrane Library
Observational study suggests a conservative approach to inpatient hypertension may be safer
4 Feb, 2021 | 01:14h | UTCTreatment and Outcomes of Inpatient Hypertension Among Adults With Noncardiac Admissions – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
#Hypertension is common in the inpatient setting, but antihypertensive intensification is not. Intensification of therapy without signs of end-organ damage is associated with worse outcomes https://t.co/y1MdZNfi9P
— JAMA Internal Medicine (@JAMAInternalMed) December 29, 2020
WHO: Consecutive drop in new COVID-19 cases ‘encouraging news’
4 Feb, 2021 | 01:37h | UTCConsecutive drop in new COVID-19 cases ‘encouraging news’: WHO – UN News
UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus
4 Feb, 2021 | 01:32h | UTCCommentary: Covid: Antibodies last at least six months in most – BBC
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
Study shows the viral load of index cases is a leading driver of SARS-CoV-2 transmission
4 Feb, 2021 | 01:35h | UTCCommentary: Understanding the drivers of transmission of SARS-CoV-2 – The Lancet Infectious Diseases
Racing the virus: Why tweaking vaccines to fight variants won’t be simple
4 Feb, 2021 | 01:28h | UTCRacing the virus: Why tweaking vaccines to fight variants won’t be simple – Reuters
Video (3 min): Sinovac and Sinopharm – what do we know about the Chinese vaccines?
4 Feb, 2021 | 01:31h | UTCSinovac and Sinopharm – what do we know about the Chinese vaccines? – BBC
[Preprint] Meta-analysis: More than 50 Long-term effects of COVID-19
4 Feb, 2021 | 01:26h | UTCMore than 50 Long-term effects of COVID-19: a systematic review and meta-analysis – medRxiv
Commentary: 80% of COVID-19 Patients May Have Lingering Symptoms, Signs — More than 50 effects persisted after acute infection, meta-analysis shows – MedPage Today (free registration required)